JP2018083843A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018083843A5 JP2018083843A5 JP2018012496A JP2018012496A JP2018083843A5 JP 2018083843 A5 JP2018083843 A5 JP 2018083843A5 JP 2018012496 A JP2018012496 A JP 2018012496A JP 2018012496 A JP2018012496 A JP 2018012496A JP 2018083843 A5 JP2018083843 A5 JP 2018083843A5
- Authority
- JP
- Japan
- Prior art keywords
- demethyl
- pharmaceutical composition
- deoxo
- compared
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- VHOPGJHKSPGXIZ-AMASXYNMSA-N 31-o-demethyl-fk506 Chemical compound COC1CC(C)C(C(C(=O)N2CCCCC2C(=O)O2)=O)(O)OC1C(OC)CC(C)C\C(C)=C\C(CC=C)C(=O)CC(O)C(C)C2C(\C)=C\C1CCC(O)C(O)C1 VHOPGJHKSPGXIZ-AMASXYNMSA-N 0.000 claims 4
- FYYHDEVDDBWQIW-UHFFFAOYSA-N 9-deoxo-31-O-demethylFK506 Natural products CC1C(O)CC(=O)C(CC=C)C=C(C)CC(C)CC(OC)C(O2)C(OC)CC(C)C2(O)CC(=O)N2CCCCC2C(=O)OC1C(C)=CC1CCC(O)C(O)C1 FYYHDEVDDBWQIW-UHFFFAOYSA-N 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 230000001506 immunosuppresive effect Effects 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2014-0099210 | 2014-08-01 | ||
| KR1020140099210A KR101694879B1 (ko) | 2014-08-01 | 2014-08-01 | 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526030A Division JP6370490B2 (ja) | 2014-08-01 | 2015-07-31 | 免疫抑制活性なしに神経再生活性が維持されるｆｋ５０６誘導体及びその用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018083843A JP2018083843A (ja) | 2018-05-31 |
| JP2018083843A5 true JP2018083843A5 (enExample) | 2018-07-26 |
| JP6851334B2 JP6851334B2 (ja) | 2021-03-31 |
Family
ID=55217893
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526030A Active JP6370490B2 (ja) | 2014-08-01 | 2015-07-31 | 免疫抑制活性なしに神経再生活性が維持されるｆｋ５０６誘導体及びその用途 |
| JP2018012496A Active JP6851334B2 (ja) | 2014-08-01 | 2018-01-29 | 免疫抑制活性なしに神経再生活性が維持されるｆｋ５０６誘導体及びその用途 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017526030A Active JP6370490B2 (ja) | 2014-08-01 | 2015-07-31 | 免疫抑制活性なしに神経再生活性が維持されるｆｋ５０６誘導体及びその用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10226446B2 (enExample) |
| EP (1) | EP3187183B1 (enExample) |
| JP (2) | JP6370490B2 (enExample) |
| KR (1) | KR101694879B1 (enExample) |
| CN (2) | CN110251511A (enExample) |
| WO (1) | WO2016018117A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101694879B1 (ko) * | 2014-08-01 | 2017-01-12 | 주식회사 인트론바이오테크놀로지 | 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도 |
| US12011497B2 (en) * | 2018-12-11 | 2024-06-18 | Molgenbio Co. Ltd. | Compounds, compositions containing same, and use thereof for promoting hair growth |
| US11449807B2 (en) | 2020-01-31 | 2022-09-20 | Walmart Apollo, Llc | Systems and methods for bootstrapped machine learning algorithm training |
| US20230137836A1 (en) * | 2020-06-19 | 2023-05-04 | Seoul National University R&Db Foundation | Novel prolylfk506 derivatives having neurite growth and synapse formation activities and uses thereof |
| CN118460433A (zh) * | 2024-06-04 | 2024-08-09 | 浙江启真合成生物技术有限公司 | 高产他克莫司的链霉菌工程菌及其构建方法与应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4894366A (en) | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
| EP1595541A1 (en) * | 2004-05-12 | 2005-11-16 | Alcasynn Pharmaceuticals Gmbh | Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin |
| CA2673863A1 (en) | 2006-12-28 | 2008-07-10 | Limerick Biopharma, Inc. | Methods and compositions for therapeutic treatment |
| WO2009158031A2 (en) * | 2008-06-27 | 2009-12-30 | Limerick Biopharma, Inc. | Methods and compositions for therapeutic treatment |
| KR101261131B1 (ko) | 2010-08-24 | 2013-05-06 | 이화여자대학교 산학협력단 | 신규 타크롤리무스 유도체, 상기 유도체를 포함하는 신경 보호용 조성물, 상기 유도체를 포함하는 면역 억제용 조성물, 상기 유도체의 생산 방법 및 상기 유도체의 생산 균주 |
| KR101632042B1 (ko) * | 2014-06-30 | 2016-06-21 | 주식회사 인트론바이오테크놀로지 | Fk506 유도체를 함유하는 크립토코쿠스 속 곰팡이 및 칸디다 속 곰팡이에 의한 진균 감염을 치료하기 위한 약제학적 조성물 및 그의 용도 |
| KR101694879B1 (ko) * | 2014-08-01 | 2017-01-12 | 주식회사 인트론바이오테크놀로지 | 면역억제활성 없이 신경재생활성이 유지되는 fk506 유도체 및 그의 용도 |
-
2014
- 2014-08-01 KR KR1020140099210A patent/KR101694879B1/ko active Active
-
2015
- 2015-07-31 WO PCT/KR2015/008031 patent/WO2016018117A1/ko not_active Ceased
- 2015-07-31 CN CN201910404660.9A patent/CN110251511A/zh active Pending
- 2015-07-31 US US15/500,353 patent/US10226446B2/en active Active
- 2015-07-31 EP EP15827244.3A patent/EP3187183B1/en active Active
- 2015-07-31 JP JP2017526030A patent/JP6370490B2/ja active Active
- 2015-07-31 CN CN201580041277.1A patent/CN106794169B/zh active Active
-
2018
- 2018-01-29 JP JP2018012496A patent/JP6851334B2/ja active Active
-
2019
- 2019-01-08 US US16/242,386 patent/US10576060B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018083843A5 (enExample) | ||
| EP4596041A3 (en) | Farnesoid x receptor agonists and uses thereof | |
| WO2017191130A3 (en) | Arginase inhibitors and their therapeutic applications | |
| AR111693A1 (es) | Compuestos de 5-metil-1,3,4-oxadiazol-2-ilo con actividad inhibitoria de oga | |
| EP4011871A3 (en) | Processes for preparing oxathiazin-like compounds | |
| MX2018002906A (es) | Metodos de tratamiento de trastornos del desarrollo con pipradrol. | |
| WO2016065226A8 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| JP2013519675A5 (enExample) | ||
| JP2016147915A5 (enExample) | ||
| EP3973586A4 (en) | NEW PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF MENTAL, BEHAVIORAL AND COGNITIVE DISORDERS | |
| EP3952840A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING MENTAL, BEHAVIORAL AND COGNITIVE DISORDERS | |
| MX2021015503A (es) | Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b. | |
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 | |
| WO2018064255A3 (en) | Antibodies that bind interleukin-2 and uses thereof | |
| JP2020536085A5 (enExample) | ||
| EP4434966A4 (en) | PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR CYTOLOGICALLY ACCEPTABLE SALT THEREOF AND COMPOSITION FOR THE PREVENTION, RELIEF OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING IT AS AN ACTIVE INGREDIENT | |
| JP2018508329A5 (enExample) | ||
| MY201535A (en) | Therapeutic compounds | |
| EP4008718C0 (en) | HETEROARYLAMIDOPYRIDINOL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING IT AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING AUTOIMMUNE DISEASE | |
| WO2017070689A3 (en) | Solabegron zwitterion and uses thereof | |
| EA201792575A1 (ru) | Фармацевтические композиции леветирацетама пролонгированного высвобождения | |
| WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
| EP4480485A3 (en) | Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions | |
| MX2020009999A (es) | Composiciones farmacéuticas para inhibir citocinas inflamatorias. | |
| JP2019505549A5 (enExample) |